Grace Therapeutics, Inc.
GRCE · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $5 | $10 | $6 |
| G&A Expenses | $7 | $0 | $8 | $10 |
| SG&A Expenses | $7 | $7 | $8 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $34 | $0 |
| Operating Expenses | $17 | $11 | $52 | $16 |
| Operating Income | -$17 | -$11 | -$52 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | -$3 | $0 | $5 |
| Pre-Tax Income | -$13 | -$15 | -$52 | -$10 |
| Tax Expense | -$3 | -$2 | -$10 | -$1 |
| Net Income | -$10 | -$13 | -$42 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.79 | -1.73 | -5.71 | -1.6 |
| % Growth | 54.3% | 69.7% | -256.9% | – |
| EPS Diluted | -0.79 | -1.73 | -5.71 | -1.6 |
| Weighted Avg Shares Out | 12 | 7 | 7 | 6 |
| Weighted Avg Shares Out Dil | 12 | 7 | 7 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$15 | -$18 | -$15 |
| % Margin | – | – | – | – |